Abstract
This study retrospectively examined the efficacy of the atypical antipsychotic risperidone in people with developmental disabilities living in institutional settings. Specifically, this study examined the impact of risperidone on clinical global impression (CGI) ratings of medical/psychiatric and behavioral status and other clinical measures. The study collected data from 294 individuals receiving either risperidone or haloperidol, alone or in combination with other psychotropic medications, from a population residing in several state-run, ICF/MR-certified developmental centers in one state. Comparisons were made on retrospective data between those receiving risperidone and those receiving haloperidol on several measures based on intensive record reviews. Clinical characteristics of subjects were related to psychotropic medications and specifically to dose ranges. Significant differences were obtained on both medical and behavioral CGI measures between the risperidone and haloperidol groups. Implications of these and other findings are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 10-20 |
| Number of pages | 11 |
| Journal | Mental Health Aspects of Developmental Disabilities |
| Volume | 7 |
| Issue number | 1 |
| State | Published - Jan 2004 |
| Externally published | Yes |
Keywords
- Atypical antipsychotics
- Clinical global impressions
- Developmental disabilities
- Institutional settings
- Intellectual disability
- Mental retardation
- Psychiatric disorder
ASJC Scopus subject areas
- Clinical Psychology
- Psychiatry and Mental health
